Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection

BACKGROUND: Fatigue is a common symptom of chronic hepatitis C virus (HCV) infection and a frequent side-effect of peginterferon/ribavirin (PR) therapy for HCV. This study evaluated the impact of adding the oral HCV NS3/4A protease inhibitor simeprevir to PR on patient-reported fatigue and health st...

Descripción completa

Detalles Bibliográficos
Autores principales: Scott, Jane, Rosa, Kathleen, Fu, Min, Cerri, Karin, Peeters, Monika, Beumont, Maria, Zeuzem, Stefan, Evon, Donna M, Gilles, Leen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162924/
https://www.ncbi.nlm.nih.gov/pubmed/25164700
http://dx.doi.org/10.1186/1471-2334-14-465

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162924/
https://www.ncbi.nlm.nih.gov/pubmed/25164700
http://dx.doi.org/10.1186/1471-2334-14-465

Ejemplares similares